Bußmann L, Busch C-J, Knecht R
Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Kopf-Hals-Chirurgie und Onkologie, Kopf-Hals-Tumorzentrum des UCCH, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland.
HNO. 2016 Oct;64(10):723-30. doi: 10.1007/s00106-016-0235-6.
This year particularly phase II studies were presented at the 2016 ASCO Annual Meeting, in which new drugs (monoclonal antibodies, small molecules) were investigated in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). Notably, there was a great number of studies investigating carcinoma of the nasopharynx. The studies presented in this article summarize the different therapeutic concepts in the treatment of R/M-HNSCC and represent the variety of therapeutic approaches in the recurrent and metastatic setting.
今年，特别是II期研究在2016年美国临床肿瘤学会（ASCO）年会上公布，这些研究针对复发性或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者对新药（单克隆抗体、小分子药物）进行了调查。值得注意的是，有大量研究针对鼻咽癌。本文中展示的研究总结了R/M-HNSCC治疗中的不同治疗理念，并代表了复发和转移情况下的多种治疗方法。
